The field of nuclear medicine has witnessed significant advancements over the years, with various radiopharmaceuticals being developed to diagnose and treat a range of diseases. One such notable development is the MIRD-226, a radiopharmaceutical that has been gaining attention in recent years due to its potential applications in nuclear medicine.

In 2018, a new radiopharmaceutical, MIRD-226, was developed to overcome these limitations. MIRD-226 is labeled with Lutetium-177 (Lu-177), a radioactive isotope with a longer half-life than Indium-111 (In-111). This allows for more efficient and prolonged treatment of NETs.

MIRD-226 works by binding to somatostatin receptors on the surface of NET cells. Once bound, the radiopharmaceutical is internalized by the cell, where the Lu-177 isotope emits beta particles that damage the tumor cells. This results in the death of the tumor cells, while minimizing damage to surrounding healthy tissues.